Search
We investigated the genetic and epigenetic regulation of the UBASH3A gene and its association with early-onset sepsis. Using matched whole blood DNA methylation, gene expression, genotypes, and immune cell counts from the EPIC-HIPC newborn cohort, we report that promoter methylation was negatively correlated with ontogenetic changes in UBASH3A gene expression and circulating CD3+ T-cell numbers.
Two RSV immunisations products: a maternal vaccine, Abrysvo, and a long-acting monoclonal antibody, nirsevimab, both designed to prevent RSV illness in infants, have recently become available. Modelling evidence is required to inform how to optimally use these products in immunisation programs to reduce the burden of RSV in young children.
Burkholderia pseudomallei is a facultative intracellular pathogen and the causative agent of melioidosis. Treatment of this deadly infection is both protracted and limited to only a select number of antibiotics. Not only can patients suffer adverse reactions to prolonged therapy, but resistance has also been reported in several clinical isolates.
Global rates of invasive Group A Streptococcus (iGAS) disease surged from September 2022, exceeding pre-COVID-19 pandemic levels, showing atypical seasonality and disproportionately affecting children. We previously described the epidemiology of iGAS among Australian children from mid-2018 to end 2022 using data from the Paediatric Active Enhanced Diseases network and here provide updated clinical epidemiology for 2023 and 2024 to help inform public health strategies.
Syphilis remains a global public health concern, particularly in pregnancy due to the risk of congenital syphilis. The WHO recommends benzathine penicillin G (BPG) as the standard treatment in pregnant women, whilst the optimal dosing strategy has not been established, particularly in relation to the impact of gestational age. This study sought to characterize the pharmacokinetics (PK) of a three-dose regimen of intramuscular BPG, given at weekly intervals, in pregnant women with syphilis.
Influenza remains an important cause of pediatric morbidity and mortality. Immunisation is critical to prevent hospitalisation and severe disease. The COVID-19 pandemic had far-reaching effects on influenza epidemiology and vaccine use.
Rhinoviruses (RV) are the most common respiratory viruses globally and a major cause of airway symptoms in children and individuals with asthma. Although more than 170 RV types exist across 3 species (RV-A, RV-B, RV-C), type-specific circulation patterns and age-related prevalence remain poorly defined.
Group A Streptococcus (Strep A) causes a wide spectrum of diseases, ranging from pharyngitis and impetigo to severe invasive infections and immune-mediated conditions such as acute rheumatic fever, rheumatic heart disease and acute post-streptococcal glomerulonephritis. Contemporary data on the global burden of Strep A diseases are lacking.
This study presents an optimised cultured ELISpot protocol for detecting central memory T-cell interferon gamma (IFNγ) responses against SARS-CoV-2 peptides following an initial priming with either peptides, or whole spike protein.
Australia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.